Celgene Settles Another Challenge to Market Generic to Revlimid in U.S. -- Update
29 März 2019 - 07:26PM
Dow Jones News
By Bowdeya Tweh
Celgene Corp. (CELG) said Friday it reached a settlement with a
drug manufacturer that would permit that firm sell a generic
version of Revlimid in the U.S. starting in 2022.
Celgene, of Summit, N.J., has granted Alvogen Pine Brook LLC the
ability to market limited quantities of generic lenalidomide after
March 2022, the drug maker said. Celgene reached a deal with Natco
Pharma Ltd. in 2015, granting the firm a license to sell the
generic in the U.S. starting in March 2022.
The generic can be sold without quantity limitations in the U.S.
after Jan. 31, 2026, Celgene said.
Alvogen's ability to market the product in the U.S. is pending
approval from the Food and Drug Administration of an abbreviated
new drug application.
Last year Revlimid generated $6.47 billion of U.S. sales and
$9.69 billion in sales world-wide.
Bristol-Myers Squibb Co. (BMY), which agreed in January to buy
Celgene for roughly $74 billion deal, said Friday the agreement
helps provide "further clarity and security around the patent
estate for Revlimid."
"We are confident in the strength of our combination with
Celgene and our ability to create a premier biopharma company with
leading franchises and a deep and broad pipeline that will drive
sustainable growth," the company said in a statement.
Write to Bowdeya Tweh at bowdeya.tweh@wsj.com
(END) Dow Jones Newswires
March 29, 2019 14:11 ET (18:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2023 bis Mär 2024